Hadn't thought of it until now however as NIH Mission Statement states they do the trials they do to understand the science of new therapies and drugs, is there a possibility the NIH DMSB suggests to the powers that be at the NIH that Covid ARDS Trial design was faulty and it's worthwhile doing another trial pronto before Covid Variants start dominating Hospitalisations in the US?
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-61
-
- There are more pages in this discussion • 363 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |